Anavex Life Sciences shares surge 24.52% intraday on clinical data momentum and regulatory optimism.

Anavex Life Sciences (AVXL) surged 24.52% intraday, driven by a confluence of clinical and regulatory developments. The rally followed the presentation of Blarcamesine’s positive Phase IIb/III data at the CTAD Alzheimer’s conference, Q4 2025 earnings highlighting a strong cash position, and renewed optimism after prior EMA setbacks. Despite a concurrent fraud investigation (linked to the November 14 EMA rejection), the immediate catalysts focused on therapeutic progress and regulatory momentum, propelling the stock to a 52-week high. Elevated intraday volume (5.75M shares) and technical indicators like an oversold RSI (19.54) further underscored short-term bullish sentiment, though long-term fundamentals remain mixed.